KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to 0.19.

  • Teva Pharmaceutical Industries' Equity Ratio rose 4196.69% to 0.19 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.19, marking a year-over-year increase of 4196.69%. This contributed to the annual value of 0.19 for FY2025, which is 4196.69% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Equity Ratio stood at 0.19, which was up 4196.69% from 0.18 recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Equity Ratio's 5-year high stood at 0.24 during Q3 2021, with a 5-year trough of 0.14 in Q4 2024.
  • Moreover, its 5-year median value for Equity Ratio was 0.19 (2025), whereas its average is 0.19.
  • Its Equity Ratio has fluctuated over the past 5 years, first plummeted by 2680.1% in 2024, then skyrocketed by 4196.69% in 2025.
  • Teva Pharmaceutical Industries' Equity Ratio (Quarter) stood at 0.24 in 2021, then fell by 17.18% to 0.2 in 2022, then decreased by 4.33% to 0.19 in 2023, then decreased by 26.8% to 0.14 in 2024, then surged by 41.97% to 0.19 in 2025.
  • Its last three reported values are 0.19 in Q4 2025, 0.18 for Q3 2025, and 0.17 during Q2 2025.